Cyclooxygenase-2: A therapeutic target

被引:536
|
作者
Turini, ME [1 ]
DuBois, RN
机构
[1] Nestle Res Ctr, Dept Nutr, CH-1000 Lausanne 26, Switzerland
[2] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Med Ctr, Dept GI & Cell Biol, Nashville, TN 37232 USA
来源
ANNUAL REVIEW OF MEDICINE | 2002年 / 53卷
关键词
cyclooxygenase; prostaglandins; biology; disease; inflammation;
D O I
10.1146/annurev.med.53.082901.103952
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cyclooxygenase (COX), also known as prostaglandin endoperoxide synthase, is the key enzyme required for the conversion of arachidonic acid to prostaglandins. Two COX isoforms have been identified, COX-1 and COX-2. In many situations, lthe COX-1 enzyme is produced constitutively (e.g., in gastric mucosa), whereas COX-2 is highly inducible (e.g., at sites of inflammation and cancer). Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both enzymes, and a new class of COX-2 selective inhibitors (COXIBs) preferentially inhibit the COX-2 enzyme. This review summarizes our current understanding of the role of COX-1 and COX-2 in normal physiology and disease.
引用
收藏
页码:35 / 57
页数:23
相关论文
共 50 条
  • [31] Cyclooxygenase-2:: A new target for epithelial cancer treatments -: Prologue
    Eschwège, P
    PRESSE MEDICALE, 2001, 30 (10): : 505 - 507
  • [32] Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer
    G. Aparicio Gallego
    S. Díaz Prado
    P. Jiménez Fonseca
    R. García Campelo
    J. Cassinello Espinosa
    L. M. Antón Aparicio
    Clinical and Translational Oncology, 2007, 9 : 694 - 702
  • [33] Cyclooxygenase-2:: a new target for epithelial cancer treatments -: Cyclooxygenases
    Eschwège, P
    de Ledinghen, V
    Camilli, T
    Kulkarni, S
    Dalbagni, G
    Droupy, S
    Jardin, A
    Benoît, G
    Weksler, BB
    PRESSE MEDICALE, 2001, 30 (10): : 511 - 514
  • [34] Selective cyclooxygenase-2 inhibition: A target in cancer prevention and treatment
    Subongkot, S
    Frame, D
    Leslie, W
    Drajeeer, D
    PHARMACOTHERAPY, 2003, 23 (01): : 9 - 28
  • [35] Microglia and cyclooxygenase-2: Possible therapeutic targets of progesterone for stroke
    Jiang, Chao
    Cui, Kefei
    Wang, Jianping
    He, Yuanhong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2011, 11 (11) : 1925 - 1931
  • [36] Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: Potential therapeutic targets
    Sirica, AE
    Lai, GH
    Endo, K
    Zhang, ZC
    Yoon, BI
    SEMINARS IN LIVER DISEASE, 2002, 22 (03) : 303 - 313
  • [37] Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome:: Therapeutic use of the cyclooxygenase-2 inhibitor nimesulide
    Nüsing, RM
    Reinalter, SC
    Peters, M
    Kömhoff, M
    Seyberth, HW
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) : 384 - 390
  • [38] Interrogation of Brain Endothelial Cell Gene Expression Reveals Cyclooxygenase-2 as a Therapeutic Target After Subarachnoid Hemorrhage
    Tso, Michael K.
    Turgeon, Paul J.
    Bosche, Bert
    Lee, Charles K.
    Nie, Tian
    D'Abbondanza, Josephine A.
    Ai, Jinglu
    Marsden, Philip A.
    Macdonald, Robert L.
    STROKE, 2017, 48
  • [39] Cyclooxygenase-2 in epilepsy
    Rojas, Asheebo
    Jiang, Jianxiong
    Ganesh, Thota
    Yang, Myung-Soon
    Lelutiu, Nadia
    Gueorguieva, Paoula
    Dingledine, Raymond
    EPILEPSIA, 2014, 55 (01) : 17 - 25
  • [40] Cyclooxygenase-2 in the kidney
    Harris, RC
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2000, 11 (12): : 2387 - 2394